January 1, 2009Thrombosis and Haemostasis

Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients

View Full Paper

Ask AI

Bookmark

Why the study?

What are the risk factors and clinical prediction rules for identifying patients at high risk of bleeding during treatment with vitamin K antagonists?

Population

Patients receiving anticoagulation with vitamin K antagonists for conditions including atrial fibrillation…

Design

Review

Authors

BCBenilde CosmiVascular Medicine GPGualtiero PalaretiVascular Medicine

Discussion

Member takes

Implication

May support VKA risk-benefit decisions via stratification; leaves open prospective validation before routine adoption.

Structured PICO

What are the risk factors and clinical prediction rules for identifying patients at high risk of bleeding during treatment with vitamin K antagonists?

Population

Patients receiving anticoagulation with vitamin K antagonists (VKAs) for conditions including atrial fibrillation (AF), venous thromboembolism (VTE), acute coronary syndromes, and after invasive cardiac procedures

Intervention

Vitamin K antagonists (VKAs) and clinical prediction rules for bleeding risk

Outcome

Risk factors for bleeding and clinical prediction rulessafety

Clinical prediction rules can help stratify bleeding risk in patients receiving vitamin K antagonists to optimize the risk/benefit ratio of anticoagulation therapy.

Cite This Study

Cosmi et al. (2009) studied this question.

synapsesocial.com/papers/69f53f26e0fbb6efbd2038cb https://doi.org/10.1160/th08-11-0730

View Full Paper

Ask AI

Bookmark

Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider